clinical trial · NCT04629729
FT819 in Subjects With B-cell Malignancies
Lymphoma, B-CellChronic Lymphocytic LeukemiaPrecursor B-Cell Acute Lymphoblastic LeukemiaFT819CyclophosphamideFludarabineIL-2Bendamustine
brief summary
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
started
Jul 12, 2021
primary completion
Jun 18, 2025
completion
Sep 30, 2039
last updated
Mar 19, 2026
official title
A Phase I Study of FT819 in Subjects With B-cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol